QualityDipStocks / Real Estate · REITs
Omega Healthcare Investors OHI
Outside our quality screen, so we don’t track its dips. It’s 9% below its 52-week high.
Outside our quality screen, trading well below our fair value estimate.
- Fair value est.
- $62.76+34%
- Market Value
- $46.55price +1%
- Off 52-wk high
- −9%
- Risk vs market
- Lowbeta −0.28
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $46.98
- 52-wk lowlowest close, 1 year$39.87−15.1%
- Market Valueavg paid since Jul 29$46.55−0.9%
- PriceFri Oct 30 close$46.98you are here
- 52-wk highhighest close, 1 year$51.72+10.1%
- Fair value est.base case$62.76+33.6%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 10.7% ±2 points. Bear = 10.5% and 8.7%; bull = 8.5% and 12.7% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is below even the bear case.
What the price implies To be worth today’s price, OHI’s free cash flow would need to grow about 5% a year for five years; our estimate uses 11%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much OHI moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 1.7× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- -0.28
- Volatility
- 22% vs 13% SPY
- Correlation SPY
- −0.17
- Correlation QQQ
- −0.26
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $62.76, 34% above the price.
ValuationP/E of 17.6× vs a 28.7× median for the 46 Real Estate companies we cover.
Cash returnsDividend yield of 5.4% ($795M paid over 12 months, 94% of earnings).
ValuationFree-cash-flow yield of 5.5% (price / FCF 18.2×): $816M of free cash in the last 12 months.
GrowthDiluted EPS grew 25% to $1.94 in FY2025.
Top bearish points 5 of 5
Cash returnsShare count up 4.3% in a year: existing holders are being diluted.
Cash returnsDividends take 94% of earnings ($795M paid over 12 months), leaving little to reinvest or raise the payout.
ValuationPrice / book of 2.8×, above the 2.6× median for the 47 Real Estate companies we cover.
QualityDoesn’t pass our quality screen: net debt 3.5× EBITDA (limit 3×).
RiskReports earnings Nov 3 (consensus EPS $0.78): results can move the price sharply and reset Market Value.
Who’s talking about it
Notable investors, executives, analysts and public figures on Omega Healthcare Investors in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in REITs
All fundamentals
P/E 17.6 · FCF yield 5.5% · ROE 16%
Valuation
- P/E
- 17.6×Real Estate median 28.7×
- Price / FCF
- 18.2×
- FCF yield
- 5.5%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 11.59×
- Price / book
- 2.76×
- Market cap
- $14.9Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $1.3B
- Sales growth, 12 months
- +15.0%vs the 12 months before
- Sales growth, 3 yrs
- +10.7%/yrfrom FY2022
- Diluted EPS, 12 months
- $2.81
- EPS growth, last FY
- +25.2%
- Net income, 12 months
- $842M
- Net income growth
- +85%12 months vs before
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- 65.7%
- FCF margin
- 63.6%
- Return on equity
- 16%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $39M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $816M
- FCF growth, 12 months
- +5%
- Dividend yield
- 5.35%$795M paid
- Payout ratio
- 94%
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +4.3%diluted shares vs a year ago
- Stock-based comp
- $53M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Omega Healthcare Investors’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $62.76 · MV $46.55 · FCF value $55.42
Assumes 10.7% growth for 5 years (revenue grew 10.7% a year FY22–FY25), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $2.58 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Jul 30, 2026.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 57 · 5 days +1.6%
The business
FCF $0.7B · Sales +11%
- Free cash flow, 12 months$0.7B
- Free-cash-flow yield4.7%
- Free-cash-flow margin53%
- Gross margin98%
- Operating margin62%
- Return on invested capital6%
- Return on equity16%
- Sales growth (latest quarter vs year-ago quarter)+11%
- Net debt / EBITDA3.5×
Next report
Nov 3
- DateTue Nov 3, after the close
- Consensus EPS$0.78
- Year-ago EPS$0.79
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
OHI is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.